Open AccessCardiology update 2017: The first quarter
Author(s) -
Sridharan Umapathy
Publication year - 2017
Publication title -
journal of the practice of cardiovascular sciences
Language(s) - English
Resource type - Journals
eISSN - 2454-2830
pISSN - 2395-5414
DOI - 10.4103/jpcs.jpcs_16_17
Subject(s) - quarter (canadian coin) , cardiology , medicine , geography , archaeology
In the first quarter of 2017, proprotein convertase subtilisin/kexin type 9's role got defined further with a number of trials such as FOURIER, ORION-1, and SPIRE 1 and 2. TAVI proves safe in intermediate-risk patients in the Surgical Replacement and Transcatheter Aortic Valve Implantation study. Newer anticoagulants extended their role to valvular heart disease. Bioabsorbable stent showed problems (ABSORB 2 and 3). New guidelines have been released for syncope and transcatheter aortic valve replacement implantation. Clinical outcome studies involving instantaneous wave-free ratio (IFR) showed IFR to be noninferior to fractional flow reserve. Optimal medical therapy proves noninferior to percutaneous coronary intervention in single vessel chronic total occlusion